Sugi Predict

Sugi Predict / Compounds / SCHEMBL29380203

SCHEMBL29380203

SCHEMBL29380203

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O)[C@H]3NC(C)=O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@H]2O)[C@H](O)[C@H]1O)NC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SIGLEC7 Q9Y286 6/20 0.57
▸ MAG P20916 6/20 0.51
▸ SELL P14151 2/20 0.51
▸ SELP P16109 2/20 0.51
▸ SELE P16581 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12313946 1.00 SIGLEC7 (0.57) SIGLEC7MAGSELLSELPSELE
SCHEMBL29699102 0.98 SIGLEC7 (0.57) SIGLEC7MAGSELLSELPSELE
SCHEMBL29355768 0.96 SELL (0.55) SIGLEC7MAGSELLSELPSELE
SCHEMBL12313945 0.96 SIGLEC7 (0.62) SIGLEC7MAGSELLSELPSELE
SCHEMBL20971391 0.96 SIGLEC7 (0.56) SIGLEC7MAGSELLSELPSELE
SCHEMBL31126371 0.96 SIGLEC7 (0.56) SIGLEC7MAGSELLSELPSELE
SCHEMBL30655036 0.96 SIGLEC7 (0.56) SIGLEC7MAGSELLSELPSELE
SCHEMBL22969674 0.96 SIGLEC7 (0.56) SIGLEC7MAGSELLSELPSELE
SCHEMBL195718 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELLSELPSELE
SCHEMBL30651017 0.96 SIGLEC7 (0.56) SIGLEC7MAGSELLSELPSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577245-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS The Johns Hopkins University (US) 2025-07-02 — — EP disclosed
US-12059454-B2 Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-08-13 — — US disclosed
WO-2024044756-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS THE JOHNS HOPKINS UNIVERSITY (US) 2024-02-29 — — WO disclosed
US-20220233659-A1 ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-07-28 — — US disclosed
US-11241487-B2 Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-02-08 — — US disclosed
Send feedback